Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab

Sponsor
ECOG-ACRIN Cancer Research Group
Study ID
NCT00898417
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • carboplatin — DRUG
  • paclitaxel — DRUG
  • proteomic profiling — GENETIC
  • laboratory biomarker analysis — OTHER
  • matrix-assisted laser desorption/ionization time of flight mass spectrometry — OTHER

Study Details

RATIONALE: Studying samples of blood in the laboratory from patients undergoing treatment for non-small cell lung cancer may help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at proteomic patterns in stored blood samples from patients undergoing treatment for non-small cell lung cancer.

Key Dates

First listed
May 12, 2009
Start date
Mar 14, 2008
Status verified
May 2017
Primary completion
Apr 14, 2008
Completion
Apr 14, 2008

Study Design

Enrollment
90 participants (actual)

Primary Outcome Measure

Survival [ Time Frame: 1 day ]

Related Studies